Oncimmune - An Alden Scientific Company

Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody / Autoantibody Biomarker Signatures. ImmunoINSIGHTS™, the best-in-class biomarker discovery engine, provides access to the B cell repertoire and a pivotal class of biomarkers. With one of the world’s largest antigen libraries covering 9000+ human antigens and multi-species variants, we profile antibodies from various biologic samples in very low volume (50 µl). Developed and curated by immunologists and a team of bioinformaticians, we offer high content biological insights and analytics powered by proprietary machine learning algorithms, models and deep knowledge mining solutions. Our platform uses Luminex xMAP® – the world’s most used multiplexing technology. At Oncimmune, our mission is to develop innovative technologies and solutions to improve the understanding of the immune system leading to more effective, targeted and safer treatments and better diagnosis. Our scientists work hand-in-hand with our clients to discover relevant and insightful biomarkers.